No Data
Calculating The Intrinsic Value Of Astria Therapeutics, Inc. (NASDAQ:ATXS)
JMP Securities Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $26
Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference
Astria Therapeutics Initiated at Market Outperform by JMP Securities
JMP Securities Initiates Astria Therapeutics Inc(ATXS.US) With Buy Rating, Announces Target Price $26
Express News | Astria Therapeutics Announces Initiation of Phase 1a Trial of Star-0310, a Potential Best-in-Class Monoclonal Antibody Ox40 Antagonist for the Treatment of Atopic Dermatitis
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
